Paragonix SherpaPak System Linked to Lower Heart Transplant Costs in New Study
Event summary
- Paragonix's SherpaPak Cardiac Transport System associated with $14,982 lower costs per patient compared to ice storage in GUARDIAN-Heart Registry analysis.
- Study evaluated 486 propensity-matched heart transplants across 18 U.S. centers.
- Monte Carlo simulations showed SherpaPak as most cost-effective in 72% of cases.
- Dr. Daniel Goldstein of Montefiore Einstein led the analysis published September 22, 2026.
The big picture
The study highlights the growing importance of organ preservation technologies in addressing the heart transplant supply-demand imbalance. As healthcare systems face rising costs, solutions that demonstrate both clinical and economic benefits are likely to gain traction. Paragonix's findings position its SherpaPak system as a potential standard in heart transplantation, particularly as programs seek to expand donor pools through extended criteria and longer ischemic times.
What we're watching
- Adoption Pace
- How quickly transplant centers will adopt SherpaPak given the cost savings evidence.
- Competitive Response
- Whether competitors will develop similar preservation technologies or challenge these findings.
- Regulatory Impact
- The potential for this data to influence reimbursement policies or insurance coverage decisions.